Management of Central Retinal Artery Occlusion: A Scientific Statement From the American Heart Association.
American Heart Association
Disease Management
Emergency Medical Services
/ methods
Humans
Neurosurgical Procedures
/ methods
Prospective Studies
Randomized Controlled Trials as Topic
/ methods
Retinal Artery
/ diagnostic imaging
Retinal Artery Occlusion
/ diagnostic imaging
Retrospective Studies
Secondary Prevention
/ methods
Tissue Plasminogen Activator
/ administration & dosage
Triage
/ methods
United States
/ epidemiology
AHA Scientific Statements
giant cell arteritis
hemodilution
ischemic stroke
paracentesis
retinal artery occlusion
thrombolytic therapy
tissue plasminogen activator
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
pubmed:
9
3
2021
medline:
6
1
2022
entrez:
8
3
2021
Statut:
ppublish
Résumé
Central retinal artery occlusion (CRAO) is a form of acute ischemic stroke that causes severe visual loss and is a harbinger of further cerebrovascular and cardiovascular events. There is a paucity of scientific information on the appropriate management of CRAO, with most strategies based on observational literature and expert opinion. In this scientific statement, we critically appraise the literature on CRAO and provide a framework within which to consider acute treatment and secondary prevention. We performed a literature review of randomized controlled clinical trials, prospective and retrospective cohort studies, case-control studies, case reports, clinical guidelines, review articles, basic science articles, and editorials concerning the management of CRAO. We assembled a panel comprising experts in the fields of vascular neurology, neuro-ophthalmology, vitreo-retinal surgery, immunology, endovascular neurosurgery, and cardiology, and document sections were divided among the writing group members. Each member received an assignment to perform a literature review, synthesize the data, and offer considerations for practice. Multiple drafts were circulated among the group until consensus was achieved. Acute CRAO is a medical emergency. Systems of care should evolve to prioritize early recognition and triage of CRAO to emergency medical attention. There is considerable variability in management patterns among practitioners, institutions, and subspecialty groups. The current literature suggests that treatment with intravenous tissue plasminogen activator may be effective. Patients should undergo urgent screening and treatment of vascular risk factors. There is a need for high-quality, randomized clinical trials in this field.
Identifiants
pubmed: 33677974
doi: 10.1161/STR.0000000000000366
doi:
Substances chimiques
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e282-e294Commentaires et corrections
Type : ErratumIn